Clinical Pharmacology & TherapeuticsVolume 95, Issue 2 p. 137-137 Letters to the Editor Response to “A Case of 5-FU-Related Severe Toxicity Associated With the P.Y186C DPYD Variant” S M Offer, S M Offer Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USASearch for more papers by this authorR B Diasio, Corresponding Author R B Diasio diasio.robert@mayo.edu Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA Mayo Clinic Cancer Center, Rochester, Minnesota, USASearch for more papers by this author S M Offer, S M Offer Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USASearch for more papers by this authorR B Diasio, Corresponding Author R B Diasio diasio.robert@mayo.edu Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA Mayo Clinic Cancer Center, Rochester, Minnesota, USASearch for more papers by this author First published: 09 October 2013 https://doi.org/10.1038/clpt.2013.207Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume95, Issue2Supply Chain Management & Personalized MedicineFebruary 2014Pages 137-137 RelatedInformation